Evidence map›Paper›PMID 32755273›Full record

Trial reportJournal of psychopharmacology (Oxford, England)2020

The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers.

Will Lawn, James Hill, Chandni Hindocha, Jocelyn Yim, Yumeya Yamamori, Gus Jones, Hannah Walker, Sebastian F Green, Matthew B Wall, Oliver D Howes and 3 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of psychopharmacology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Individual and combined effects of cannabidiol and ΔJournal of psychopharmacology (Oxford, England) · 2022
    Article
  8. Frontiers in pharmacology · 2022
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Will LawnClinical Psychopharmacology Unit, University College London, London, UK.ORCID 0000-0002-0143-2724
James HillTranslational Psychiatry Research Group, University College London, London, UK.
Chandni HindochaClinical Psychopharmacology Unit, University College London, London, UK.ORCID 0000-0003-1692-7401
Jocelyn YimTranslational Psychiatry Research Group, University College London, London, UK.
Yumeya YamamoriTranslational Psychiatry Research Group, University College London, London, UK.
Gus JonesTranslational Psychiatry Research Group, University College London, London, UK.
Hannah WalkerTranslational Psychiatry Research Group, University College London, London, UK.
Sebastian F GreenTranslational Psychiatry Research Group, University College London, London, UK.ORCID 0000-0003-0773-0658
Matthew B WallClinical Psychopharmacology Unit, University College London, London, UK.
Oliver D HowesPsychiatric Imaging Group, Imperial College London, London, UK.
H Valerie CurranClinical Psychopharmacology Unit, University College London, London, UK.
Tom P FreemanClinical Psychopharmacology Unit, University College London, London, UK.
Michael Ap BloomfieldClinical Psychopharmacology Unit, University College London, London, UK.ORCID 0000-0002-1972-4610
University College London · GBUniversity College Hospital · GBHammersmith Hospital · GBImperial College London · GB

Funding

Medical Research Council MC_U120097115
6 · The paper itself

Abstract

backgroundCannabidiol has potential therapeutic benefits for people with psychiatric disorders characterised by reward function impairment. There is existing evidence that cannabidiol may influence some aspects of reward processing. However, it is unknown whether cannabidiol acutely affects brain function underpinning reward anticipation and feedback. HYPOTHESES: We predicted that cannabidiol would augment brain activity associated with reward anticipation and feedback.

methodsWe administered a single 600 mg oral dose of cannabidiol and matched placebo to 23 healthy participants in a double-blind, placebo-controlled, repeated-measures design. We employed the monetary incentive delay task during functional magnetic resonance imaging to assay the neural correlates of reward anticipation and feedback. We conducted whole brain analyses and region-of-interest analyses in pre-specified reward-related brain regions.

resultsThe monetary incentive delay task elicited expected brain activity during reward anticipation and feedback, including in the insula, caudate, nucleus accumbens, anterior cingulate and orbitofrontal cortex. However, across the whole brain, we did not find any evidence that cannabidiol altered reward-related brain activity. Moreover, our Bayesian analyses showed that activity in our regions-of-interest was similar following cannabidiol and placebo. Additionally, our behavioural measures of motivation for reward did not show a significant difference between cannabidiol and placebo. DISCUSSION: Cannabidiol did not acutely affect the neural correlates of reward anticipation and feedback in healthy participants. Future research should explore the effects of cannabidiol on different components of reward processing, employ different doses and administration regimens, and test its reward-related effects in people with psychiatric disorders.

Indexed as

RewardAdultAnticipation, PsychologicalBrain MappingCannabidiolCannabinoid Receptor ModulatorsCerebral CortexDelay DiscountingDouble-Blind MethodFeedback, PsychologicalFemaleHumansMagnetic Resonance ImagingMaleMotivationYoung AdultCannabidiolCannabinoid Receptor ModulatorsanticipationCannabidiolcannabisfeedbackfunctional magnetic resonance imagingmarijuanamotivationreward

Identifiers

PMID32755273
PMCPMC7745615
OpenAlexW3046925195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.